ABX464 First in Man, Open Label, Parallel Group, Single Ascending Dose Study.
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2016
At a glance
- Drugs ABX 464 (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man
- Sponsors Abivax
- 20 Dec 2016 Results published in the Journal of Antimicrobial Chemotherapy
- 30 Dec 2014 New trial record
- 01 Dec 2014 Results published in an Abivax media release.